In an unexpected move, the Food and Drug Administration has scolded a drug maker because one of its sales reps discussed unapproved uses of a medicine at a luncheon meeting for physicians.

The episode involved an Eisai sales rep, who made the remarks about the Fycompa epilepsy drug, according to a letter the agency sent the drug maker last week and posted on its website on Wednesday. It is not clear what unapproved use the rep was discussing or the details of the event, however, because portions of the letter were redacted.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy